Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53 peptide vaccination after cyclophosphamide for recurrent ovarian cancer
NL-OMON27620Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2008
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of p53 synthetic long peptide vaccine and cyclophosphamide in ovarian cancer and recurrent ovarian cancer (ROC), sponsored by University Medical Center Groningen. Primary endpoints: Clinical response and Immunogenicity. Started Sep 2008; status: recruiting.
02
Drugs
p53 synthetic long peptide vaccinecyclophosphamide
03
Conditions
ovarian cancerrecurrent ovarian cancer (ROC)
Beyond the preview
Go deeper on NL-OMON27620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27620.